Solid Biosciences Inc. (SLDB) — SEC Financial Statements & Analysis

Solid Biosciences Inc. (SLDB) is a biological products, (no diagnostic substances) company, incorporated in DE. Solid Biosciences Inc. trades on Nasdaq as: SLDB. Solid Biosciences Inc. (SLDB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Solid Biosciences Inc. carries a market cap of $1.44B, a P/E ratio of -6.93x, a P/B ratio of 3.84x, a P/S ratio of 26.26x, an enterprise value of $1.27B, and an EV/EBITDA multiple of -6.05x. On profitability, it posts an operating margin of -6054.70%, a net margin of -4718.44%, a Return on Equity (ROE) of -65.50%, a Return on Assets (ROA) of -56.83%, and a Return on Invested Capital (ROIC) of -127.91%. Per share, it reports EPS of $-1.44, diluted EPS of $-1.44, free cash flow per share of $-1.31, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 34.41% year-over-year, and EPS growth of -11.94% year-over-year. On the balance sheet, it maintains a current ratio of 13.82x, a quick ratio of 13.24x, working capital of $366.52M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -622.15x, free cash flow of $-187.81M (TTM), and net debt of $-160.74M. Figures sourced from SEC EDGAR.

Market Cap

$1.44B

P/E TTM

-6.93x

EPS TTM

$-1.44

P/B TTM

3.84x

ROE TTM

-65.50%

ROA TTM

-56.83%

Debt To Equity

0.12x

Free Cash Flow TTM

$-187.81M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR